COMMUNIQUÉS West-GlobeNewswire

Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024

28/08/2024 - 13:00

LONDON and BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced [...]

EDAP Reports Second Quarter 2024 Financial Results

28/08/2024 - 13:00

Record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% over Q2 2023 Record first half 2024 total worldwide revenue of EUR 30.7 million (USD 33.1 million) increased 5.6% over first [...]

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

28/08/2024 - 13:00

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein [...]

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway

28/08/2024 - 13:00

New Data Further Elucidates Bemnifosbuvir’s Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses BOSTON, [...]

KSQ Therapeutics to Participate in Upcoming Investor Conferences

28/08/2024 - 13:00

LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics ® discovery platform, today [...]

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

28/08/2024 - 13:00

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

28/08/2024 - 13:00

Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Jeune [...]

Medigene to Present at Upcoming Investor Conferences

28/08/2024 - 11:00

Planegg/Martinsried, August 28, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]

KFSHRC Advances Diversity and Inclusion in Medical Education

28/08/2024 - 09:37

RIYADH, Saudi Arabia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) reaffirms its commitment to inclusivity and diversity in medical education, establishing itself as a [...]

PulseSight Therapeutics Confirms H2 2024 Conference Schedule

28/08/2024 - 09:00

PARIS, Aug. 28, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to [...]

Aino Health reveals the top 10 real causes of sickness absence

28/08/2024 - 08:30

Aino Health presents a nordic milestone to increase employee engagement and save millions of EUR, to secure tens of thousands of jobs in companies and to solve the acute staffing shortage in the public sector. "By [...]

Du soin au lien : le KFSHRC défend l’engagement communautaire

28/08/2024 - 08:27

RIYAD, Arabie Saoudite, 28 août 2024 (GLOBE NEWSWIRE) -- Conformément aux objectifs de la Vision 2030 de l’Arabie saoudite concernant les soins de santé, le King Faisal Specialist Hospital & Research Centre (KFSHRC [...]

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk

28/08/2024 - 07:15

Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction 1 Results add to growing body of evidence for Leqvio across [...]

PCI Biotech first half 2024 interim results

28/08/2024 - 07:00

Oslo (Norway), 28 August 2024 – PCI Biotech (OSE: PCIB), today announces its interim first half 2024 results. Please find enclosed the interim report and presentation. Highlights review Operations PCI Biotech’s 2024 [...]

argenx to Present at Upcoming Investor Conferences

28/08/2024 - 07:00

August 28, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]

Avance Clinical Wins 2024 Frost & Sullivan Award for Global Biotech CRO Excellence

28/08/2024 - 05:42

ADELAIDE, Australia and WAKE FOREST, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, a leading global CRO specializing in clinical trials for the biotech sector, has won the prestigious 2024 Frost & [...]

Angelalign Technology Inc. Reports Strong Growth in Global Operations for 1H 2024

28/08/2024 - 04:56

SHANGHAI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- On August 22, 2024, Angelalign Technology Inc. ("Angel Aligner" or the "Company") announced its financial results for the first half of 2024, highlighting the Company's global [...]

Mesoblast Financial Results and Corporate Update Webcast

28/08/2024 - 01:25

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]

Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent

28/08/2024 - 01:12

MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and [...]